| dc.contributor.author | Ekmekci, OB | |
| dc.contributor.author | Ekmekci, Hakan | |
| dc.date.accessioned | 2021-03-06T10:53:09Z | |
| dc.date.available | 2021-03-06T10:53:09Z | |
| dc.identifier.citation | Ekmekci O., Ekmekci H., "Vitronectin in atherosclerotic disease", CLINICA CHIMICA ACTA, cilt.368, ss.77-83, 2006 | |
| dc.identifier.issn | 0009-8981 | |
| dc.identifier.other | av_ec7b5c05-a184-41cb-9c15-968d6ddab3d0 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/155266 | |
| dc.identifier.uri | https://doi.org/10.1016/j.cca.2005.12.015 | |
| dc.description.abstract | Atherosclerosis is characterized by the development of an intimal thickening that contains monocytes, T lymphocytes, and smooth muscle cells within an accumulation of lipid and extracellular matrix proteins. Vitronectin is a plasma glycoprotein implicated as a regulator of diverse physiological process, including blood coagulation, fibrinolysis, pericellular proteolysis, complement dependent immune responses, and cell attachment and spreading. Because of its ability to bind platelet glycoproteins and mediate platelet adhesion and aggregation at sites of vascular injury, vitronectin has become an important mediator in the pathogenesis of coronary atherosclerosis. (c) 2005 Elsevier B.V. All rights reserved. | |
| dc.language.iso | eng | |
| dc.subject | Tıp | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | Klinik Tıp | |
| dc.subject | TIBBİ LABORATUVAR TEKNOLOJİSİ | |
| dc.title | Vitronectin in atherosclerotic disease | |
| dc.type | Makale | |
| dc.relation.journal | CLINICA CHIMICA ACTA | |
| dc.contributor.department | , , | |
| dc.identifier.volume | 368 | |
| dc.identifier.startpage | 77 | |
| dc.identifier.endpage | 83 | |
| dc.contributor.firstauthorID | 71734 | |
